<qa>  What is the hazard of first progression or death of each experimental regimen relative to?I. Estimate the probability of a dose limiting toxicity DLT following cycle 1 of experimental regimens pegylated liposomal doxorubicin hydrochloride pegylated liposomal doxorubicin PLD and atezolizumab and PLDbevacizumab and atezolizumab. Safety lead-in II. Estimate and compare the hazard of first progression or death progression free survival PFS of each experimental regimen relative to the reference regimen, PLD and bevacizumab. Phase II study III. Estimate and compare the hazard of death and the hazard of first progression or death PFS of each experimental regimen relative to the reference regimen. Phase III 